Drug intelligence / Profile preview

Shenbailing

Development stage: Unknown
Lead developer: Caigang Liu
Modality: Small Molecules
Administration: Oral

Overview

Shenbailing is a Traditional Chinese Medicine (TCM) formulation, typically administered in granule form, used as an adjuvant therapy for patients following breast cancer surgery. It is specifically designed to alleviate cancer-related fatigue (CRF) and improve the overall quality of life in the post-operative recovery phase. The formulation is based on TCM principles of tonifying Qi and strengthening the spleen to address the physical exhaustion and functional decline often associated with malignancy and surgical intervention. Clinical research led by Caigang Liu at Shengjing Hospital of China Medical University evaluates its efficacy in real-world settings, focusing on its role in supportive oncological care.

Brand names: Shenbailing
Other names: Shenbailing granulesShenbailing Keli参百苓

Beyond the preview

Go deeper on Shenbailing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenbailing.

Explore the full profile